HK1202262A1 - Drug combination of beta agonist and a progestin for the treatment of muscle loss - Google Patents

Drug combination of beta agonist and a progestin for the treatment of muscle loss

Info

Publication number
HK1202262A1
HK1202262A1 HK15102807.2A HK15102807A HK1202262A1 HK 1202262 A1 HK1202262 A1 HK 1202262A1 HK 15102807 A HK15102807 A HK 15102807A HK 1202262 A1 HK1202262 A1 HK 1202262A1
Authority
HK
Hong Kong
Prior art keywords
progestin
treatment
drug combination
muscle loss
beta agonist
Prior art date
Application number
HK15102807.2A
Other languages
English (en)
Chinese (zh)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707931A external-priority patent/GB0707931D0/en
Priority claimed from GB0707930A external-priority patent/GB0707930D0/en
Priority claimed from GB0710101A external-priority patent/GB0710101D0/en
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of HK1202262A1 publication Critical patent/HK1202262A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
HK15102807.2A 2007-04-24 2015-03-19 Drug combination of beta agonist and a progestin for the treatment of muscle loss HK1202262A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0707931A GB0707931D0 (en) 2007-04-24 2007-04-24 New Therapeutic use
GB0707930A GB0707930D0 (en) 2007-04-24 2007-04-24 New therapeutic use
GB0710101A GB0710101D0 (en) 2007-05-25 2007-05-25 New Therapeutic use

Publications (1)

Publication Number Publication Date
HK1202262A1 true HK1202262A1 (en) 2015-09-25

Family

ID=39639100

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102807.2A HK1202262A1 (en) 2007-04-24 2015-03-19 Drug combination of beta agonist and a progestin for the treatment of muscle loss

Country Status (16)

Country Link
US (1) US8653052B2 (ko)
EP (1) EP2155180B1 (ko)
JP (1) JP5627452B2 (ko)
KR (1) KR101546977B1 (ko)
CN (2) CN101730547A (ko)
AU (1) AU2008240379B2 (ko)
BR (1) BRPI0810461A2 (ko)
CA (1) CA2721739C (ko)
DK (1) DK2155180T3 (ko)
EA (1) EA018918B1 (ko)
ES (1) ES2592289T3 (ko)
HK (1) HK1202262A1 (ko)
IL (1) IL201426A (ko)
MX (1) MX2009011294A (ko)
NZ (1) NZ580975A (ko)
WO (1) WO2008129308A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942009D1 (de) 1998-10-15 2010-03-25 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
AU2006270165B2 (en) 2005-07-14 2010-03-11 Neothetics, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
CN106459147B (zh) * 2014-08-05 2021-08-06 拉夸里亚创药株式会社 作为生长激素释放肽受体激动剂的丝氨酸衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308157B1 (en) 1987-09-15 1997-02-26 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
DK1494649T3 (da) * 2002-04-12 2012-04-10 Alkermes Pharma Ireland Ltd Nanopartikel-megestrolformuleringer
ES2245612B1 (es) * 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
JP2009526087A (ja) * 2005-12-22 2009-07-16 アナボレックス， インコーポレイテッド 悪液質の予防および処置のための組成物および方法
US7947579B2 (en) * 2006-02-13 2011-05-24 Stc.Unm Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition

Also Published As

Publication number Publication date
NZ580975A (en) 2012-10-26
IL201426A (en) 2016-09-29
CN101730547A (zh) 2010-06-09
BRPI0810461A2 (pt) 2014-10-14
WO2008129308A2 (en) 2008-10-30
KR101546977B1 (ko) 2015-08-24
US8653052B2 (en) 2014-02-18
JP2010525044A (ja) 2010-07-22
IL201426A0 (en) 2010-05-31
US20100130456A1 (en) 2010-05-27
EP2155180A2 (en) 2010-02-24
CA2721739A1 (en) 2008-10-30
AU2008240379B2 (en) 2012-10-04
KR20100017205A (ko) 2010-02-16
WO2008129308A3 (en) 2009-12-17
DK2155180T3 (en) 2016-09-12
EA018918B1 (ru) 2013-11-29
ES2592289T3 (es) 2016-11-29
MX2009011294A (es) 2010-01-29
JP5627452B2 (ja) 2014-11-19
EP2155180B1 (en) 2016-07-13
EA200970957A1 (ru) 2010-04-30
CN104306381A (zh) 2015-01-28
CA2721739C (en) 2016-08-23
AU2008240379A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
IL192299A0 (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
PL2073860T3 (pl) Powłoki uwalniające lek do urządzeń medycznych
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
IL174352A0 (en) Medical devices for use with carpules
HK1148940A1 (en) Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
GB0625659D0 (en) Therapeutic compounds and their use
IL202515A (en) Thyroid-like compounds and their use in the preparation of drugs for the treatment of @ metabolic diseases
GB0724251D0 (en) Therapeutic compounds and their use
GB0722680D0 (en) Therapeutic compounds and their use
IL236360A0 (en) Inhalable medicine
HK1202262A1 (en) Drug combination of beta agonist and a progestin for the treatment of muscle loss
PL2121025T3 (pl) Sposoby i kompozycje dla dostarczania czynnika terapeutycznego
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
EP2236148A4 (en) MEDIinic agent for HELICOBACTER treatment
ZA201201028B (en) Fgf receptor-activating n-acyl octasaccharides,preparation thereof,and therapeutic use thereof
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
GB201008606D0 (en) Method and medicament for pain management
IL202474A0 (en) 1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof
EP2148719A4 (en) DEVICES AND METHODS FOR DRUG DELIVERY
IL197033A0 (en) Single use self-disabling syringe
GB0705517D0 (en) Therapeutic compounds and their use
ZA201005397B (en) 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivative,use thereof,and medicament containing said derivative
GB0614538D0 (en) Therapeutic Compounds And Their Use